Tempus AI, Inc.
TEM
Peringkat dalam Saham
#1812
Tempus AI, Inc. operates as a healthcare technology company in the United... Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
Harga Saham
$67.43
Kapitalisasi Pasar
$11.83B
Perubahan (1 hari)
4.80%
Perubahan (1 tahun)
-27.06%
Negara
US
Perdagangan Tempus AI, Inc. (TEM)
Kategori
Healthcare
Pendapatan untuk Tempus AI, Inc. (TEM)
Pendapatan pada Jun 2026 TTM: $1.43B
Menurut laporan keuangan terbaru dari Tempus AI, Inc., pendapatan saat ini (TTM) adalah $1.43B. Pada tahun 2023, perusahaan menghasilkan pendapatan sebesar $531.82M peningkatan dibandingkan pendapatan pada tahun 2022 yang sebesar $320.67M. Pendapatan adalah jumlah total yang dihasilkan dari penjualan barang atau jasa. Tidak seperti laba, tidak ada pengeluaran yang dikurangkan.
Riwayat pendapatan Tempus AI, Inc. dari 2019 hingga 2026
Pendapatan pada akhir setiap tahun
| Tahun | Pendapatan | Mengubah |
|---|---|---|
| 2026 (TTM) | $1.43B | 106.52% |
| 2024 | $693.40M | 30.38% |
| 2023 | $531.82M | 65.85% |
| 2022 | $320.67M | 24.36% |
| 2021 | $257.85M | 37.15% |
| 2020 | $188.00M | 202.95% |
| 2019 | $62.06M | 0.00% |
Pendapatan untuk perusahaan serupa atau pesaing
| Perusahaan | Pendapatan | Perbedaan Pendapatan | Negara |
|---|---|---|---|
| $20.24B | 1,313.60% |
US
|
|
| $184.56M | -87.11% |
AU
|
|
| $14.37B | 903.59% |
US
|
|
| $616.91M | -56.92% |
US
|
|
| - | - |
US
|
